

# Candida Vitale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3637216/publications.pdf>

Version: 2024-02-01

94  
papers

1,330  
citations

361413

20  
h-index

395702

33  
g-index

95  
all docs

95  
docs citations

95  
times ranked

2429  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
2	CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. <i>Frontiers in Oncology</i> , 2020, 10, 849.	2.8	62
3	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	7.2	61
4	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021, 35, 737-746.	7.2	61
5	Anergic bone marrow V $\beta$ 9V $\delta$ 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. <i>Oncolmunology</i> , 2015, 4, e1047580.	4.6	58
6	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
7	Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. <i>Annals of Oncology</i> , 2016, 27, 1100-1106.	1.2	54
8	Dysfunctional V $\beta$ 9V $\delta$ 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	1.4	51
9	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	4.8	45
10	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2016, 101, e254-e258.	3.5	40
11	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	1.4	40
12	HIF-1 $\alpha$ is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	3.5	39
13	Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 594556.	4.8	39
14	V $\beta$ 9V $\delta$ 2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2419-2432.	5.4	35
15	The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. <i>Leukemia</i> , 2015, 29, 356-368.	7.2	33
16	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015, 6, 29833-29846.	1.8	33
17	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	1.4	30
18	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	2.2	29

#	ARTICLE	IF	CITATIONS
19	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. <i>Clinical Cancer Research</i> , 2016, 22, 2359-2367.	7.0	28
20	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. <i>Cancers</i> , 2020, 12, 282.	3.7	22
21	CD200 included in a 4â€marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 543-546.	1.7	21
22	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-NaÃve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	3.7	16
23	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	3.7	16
24	Richter Syndrome in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 43-51.	2.3	15
25	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. <i>Blood Advances</i> , 2021, , .	5.2	14
26	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1077-1089.	1.8	13
27	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	1.7	13
28	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	1.8	13
29	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2017, 99, 306-314.	2.2	12
30	Targeting HIF-1± Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. <i>Cancers</i> , 2021, 13, 2883.	3.7	12
31	Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3856.	3.7	12
32	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1284-1315.	3.0	12
33	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. <i>Blood</i> , 2009, 114, 2333-2333.	1.4	12
34	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. <i>Experimental Hematology</i> , 2009, 37, 728-738.	0.4	10
35	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2021, 137, 2267-2271.	1.4	10
36	Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3452-3454.	1.3	9

#	ARTICLE	IF	CITATIONS
37	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 411-425.	1.8	9
38	CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. Leukemia Research, 2019, 83, 106169.	0.8	8
39	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. Blood Cancer Journal, 2020, 10, 92.	6.2	7
40	t(9;22) as secondary alteration in core-binding factor <i>de novo</i> acute myeloid leukemia. American Journal of Hematology, 2015, 90, E211-2.	4.1	6
41	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. Journal of Personalized Medicine, 2021, 11, 249.	2.5	6
42	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. Blood, 2018, 132, 3118-3118.	1.4	6
43	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. Journal of Clinical Medicine, 2022, 11, 2076.	2.4	6
44	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. American Journal of Hematology, 2022, 97, .	4.1	5
45	A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 1878-1880.	1.3	4
46	External validation of the accuracy of â€˜CLLflow scoreâ€™™. Journal of Investigative Medicine, 2018, 66, e6-e6.	1.6	4
47	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. Cancers, 2020, 12, 1773.	3.7	4
48	Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia. Haematologica, 2019, 104, 9-12.	3.5	3
49	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. Blood, 2016, 128, 2038-2038.	1.4	3
50	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. Blood, 2020, 136, 25-26.	1.4	3
51	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, , 1-4.	1.3	3
52	Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. Frontiers in Oncology, 0, 12, .	2.8	3
53	Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. American Journal of Hematology, 2016, 91, E274-6.	4.1	2
54	Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. Journal of Geriatric Oncology, 2020, 11, 19-23.	1.0	2

#	ARTICLE	IF	CITATIONS
55	The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 885-894.	2.2	2
56	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	1.4	2
57	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3031-3031.	1.4	2
58	Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5292-5292.	1.4	2
59	LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3211-3211.	1.4	2
60	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
61	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020, 136, 54-55.	1.4	2
62	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	5.2	2
63	CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 4239.	3.7	1
64	Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 5656-5656.	1.4	1
65	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
66	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
67	Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5507-5519.	2.0	1
68	Bleeding Diathesis Associated with Acquired von Willebrand Syndrome in Three Patients with Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S201.	0.4	0
69	Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S26.	0.4	0
70	Other cancers in long-term survivor patients with chronic lymphocytic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S26-S27.	0.4	0
71	The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S42.	0.4	0
72	Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S41.	0.4	0

#	ARTICLE	IF	CITATIONS
73	LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.	0.4	0
74	Regulation of HIF-1 $\hat{\pm}$ in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.4	0
75	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278-S279.	0.4	0
76	CLL-131: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S222.	0.4	0
77	CLL-220: Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S224-S225.	0.4	0
78	Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 917-917.	1.4	0
79	The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. <i>Blood</i> , 2010, 116, 3602-3602.	1.4	0
80	IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. <i>Blood</i> , 2010, 116, 2431-2431.	1.4	0
81	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 735-735.	1.4	0
82	Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2898-2898.	1.4	0
83	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 3881-3881.	1.4	0
84	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012, 120, 3878-3878.	1.4	0
85	Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting. <i>Blood</i> , 2013, 122, 4112-4112.	1.4	0
86	The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 833-833.	1.4	0
87	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , 2015, 126, 2925-2925.	1.4	0
88	IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 4136-4136.	1.4	0
89	Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL Treated with Ofatumumab and Lenalidomide. <i>Blood</i> , 2015, 126, 1748-1748.	1.4	0
90	HIF-1 $\hat{\pm}$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance. Blood, 2016, 128, 3210-3210.	1.4	0
92	Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs. Blood, 2019, 134, 3044-3044.	1.4	0
93	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. Blood, 2020, 136, 30-31.	1.4	0
94	Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells. , 2019, , .		0